Europäische Union - Deutsch - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - thalidomid - multiples myelom - immunsuppressiva - thalidomide bms in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. thalidomide bms is prescribed and dispensed according to the thalidomide celgene pregnancy prevention programme (see section 4.

Europäische Union - Deutsch - EMA (European Medicines Agency)

lipomed gmbh - thalidomid - multiples myelom - immunsuppressiva - thalidomide lipomed in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy. thalidomide lipomed is prescribed and dispensed in accordance with the thalidomide lipomed pregnancy prevention programme (see section 4.

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

as grindeks - lenalidomide ammonium chloride - hartkapsel - 2,5 mg - lenalidomide ammonium chloride 3.016 mg - lenalidomide

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

as grindeks - lenalidomide ammonium chloride - hartkapsel - 5 mg - lenalidomide ammonium chloride 6.032 mg - lenalidomide

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

as grindeks - lenalidomide ammonium chloride - hartkapsel - 7,5 mg - lenalidomide ammonium chloride 9.048 mg - lenalidomide

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

as grindeks - lenalidomide ammonium chloride - hartkapsel - 10 mg - lenalidomide ammonium chloride 12.064 mg - lenalidomide

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

as grindeks - lenalidomide ammonium chloride - hartkapsel - 15 mg - lenalidomide ammonium chloride 18.096 mg - lenalidomide

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

as grindeks - lenalidomide ammonium chloride - hartkapsel - 20 mg - lenalidomide ammonium chloride 24.128 mg - lenalidomide

Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

as grindeks - lenalidomide ammonium chloride - hartkapsel - 25 mg - lenalidomide ammonium chloride 30.16 mg - lenalidomide

Europäische Union - Deutsch - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - immunsuppressiva - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ist indiziert für die behandlung erwachsener patienten mit zuvor unbehandeltem multiplen myelom, die nicht die voraussetzungen für eine transplantation. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 und 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ist indiziert für die behandlung erwachsener patienten mit zuvor unbehandeltem multiplen myelom, die nicht die voraussetzungen für eine transplantation. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 und 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).